BioXell S.p.A. Completes Recruitment For Phase IIb Trial Of Elocalcitol In Benign Prostatic Hyperplasia
Published: Dec 15, 2006
MILAN, Italy, Dec. 15, 2006 (PRIME NEWSWIRE) -- BioXell S.p.A. (SWX:BXLN) today announced that it has completed recruitment on schedule for its Phase IIb trial of lead compound Elocalcitol in Benign Prostatic Hyperplasia (BPH). With 532 randomized patients, the trial exceeds by 20 the planned sample size and represents the largest trial run by BioXell until now. Last patient visits are planned for June 2007, with results to be announced in the second half of 2007.